News
Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide.
Novo Nordisk has abandoned a kidney disease drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3bn.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback